Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Possible Link Between Diet and Colon Cancer Remains Unclear

May 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 5
Volume 10
Issue 5

BETHESDA, Md-Evidence of a relationship between diet and the origins of colorectal cancer is tantalizing but shadowy, two longtime researchers said at the Colorectal Cancer Prevention and Treatment conference, co-sponsored by the Cancer Research Foundation of America and the American Digestive Health Foundation.

BETHESDA, Md—Evidence of a relationship between diet and the origins of colorectal cancer is tantalizing but shadowy, two longtime researchers said at the Colorectal Cancer Prevention and Treatment conference, co-sponsored by the Cancer Research Foundation of America and the American Digestive Health Foundation.

"Nutritional factors associated with adenoma formation are likely important in the development of cancer, but there is much uncertainty," said Arthur Schatzkin, MD, DrPH, chief of the Nutritional Epidemiology Branch of the National Cancer Institute.

It is unreasonable to expect one single factor to explain the relationship between diet and colon cancer, warned Edward Giovannucci, MD, ScD, of the Harvard School of Public Health. "The old high-fat, low-fiber hypothesis for colorectal carcinogenesis is too simplistic," he said.

That long-standing hypothesis, Dr. Schatzkin said, focuses on dietary elements that are presumed to increase risk—fat, meat (especially red and processed meats), high-temperature cooking, sugar, and alcohol—and those that are thought to decrease risk—vitamins (especially A, D, and folic acid), minerals (calcium and selenium), fiber, and fruits and vegetables.

Trials with APC knockout mice, which are genetically engineered to produce intestinal adenomas, have shown that a low-fat, high-fiber diet produces a 36% reduction in small, intestinal polyps, Dr. Schatzkin said. Comparisons with humans are not simple, but this dietary intervention study does demonstrate that dietary manipulation can interfere with the carcinogenic processes.

Observational studies in humans, he said, have shown increased relative risk for total fat (2.3) and for red meat vs chicken and fish (1.8), and protection by fiber (0.4) and vegetables (0.5), for highest vs lowest quintiles. But findings diminish with time, and prospective studies show less effect, especially for fiber. The problem with observational studies is that multiple other factors—not just diet—may confound the effect.

As an example, he cited the Polyp Prevention Trial he carried out with Elaine Lanza, PhD, a decade ago. They hypothesized that a low-fat diet, high in fiber and fruits and vegetables, would decrease the recurrence of colorectal adenomas. Their targets were fat as 20% of total energy intake; 18 g/1,000 kcal of fiber daily; and 5 to 8 servings of fruits and vegetables daily.

Drs. Schatzkin and Lanza randomized 2,000 patients who had had at least one polyp removed into two groups, one with the usual diet and one with the intervention diet and intensive nutritional counseling. The latter included recipe development, newsletters, social events, and a "fruit- and veg-a-thon." Colonoscopy was performed at entry and again after 1 year and 4 years.

The intervention group did lower their fat intake by one third and increased fiber by three fourths and fruit and vegetables by two thirds, he said, and 90% completed the 4-year trial. The result? "After 10 years of work and the expenditure of much money," Dr. Schatzkin said, "there was no difference in the recurrence rate, and only a hint of reduction in the largest adenomas."

These results are open to varying interpretations, he said. They may mean that dietary change, in fact, has no effect. But it could be that a longer intervention time might result in a greater observable effect. Or perhaps diet has its effects on colorectal cancer earlier or later in the process. Or possibly a more radical diet is called for, one that more explicitly cuts down on red meat, for instance.

Dr. Giovannucci pointed out that many of the risk factors for colon cancer—reduced physical activity, increased simple carbohydrate, fat, and saturated fat intake, and higher polyunsaturated-to-saturated fat ratio—are also important in diabetes. "I suspect the factors we are looking for are not luminal but systemic, such as insulin or an insulin-like growth factor," he said.

Insulin and insulin-like growth factor (IGF) enhance cell proliferation and inhibit apoptosis, he said. In animal models, direct injection of insulin increases tumor growth, as do hypercaloric diets. However, insulin resistance also increases tumor promotion. "No matter how you affect insulin resistance, it affects the tumors," he said.

Similar trials cannot be carried out on humans, Dr. Giovannucci said, but one can look at clinical conditions like diabetes or at plasma markers like post-meal insulin, fasting insulin, C-reactive peptide, IGF binding protein-2 (IGFBP-2), and triglycerides. IGF binding proteins reduce the activity of IGF-1, so high levels of IGFBP-1, which is determined by insulin levels, may reduce the risk of colon cancer, he said.

Three published studies, he said, show that higher insulin levels predict colorectal cancer risk. However, this correlation is not simple. "Insulin levels are tied to lifestyle issues. Diet is important but is not the only issue. Someone who is overweight and inactive will have increased post-meal insulin levels," he said.

More than 50 studies have shown an inverse risk of colon cancer with physical activity, both leisure and occupational, in both men and women, across a variety of populations. "Walking 3 hours a week appears to have a major impact on development of the disease," he said.

Red meat may have a direct, deleterious effect on insulin resistance or may be a marker for other dietary patterns. The polyunsaturated-to-saturated fat ratio is also an important determinant of insulin resistance. "Fiber may be important, but the question is, how important?" Dr. Giovannucci asked. "We have to look at a constellation of factors."

So what does the conscientious physician say about this welter of factors to an inquiring population? "Risk reduction is a matter of total lifestyle," Dr. Giovannucci said. "Start with increased physical activity. Cut down on red meats, and increase your intake of fruits and vegetables. There may be a lifetime impact on risk that is hard to discern in the short term."

Articles in this issue

Adjuvant Chemo Dose Reductions Frequent in Breast Cancer
Women May Be at Greater Risk for Undertreatment of Cancer Pain
Umbilical Cord Blood in Adult Leukemia Patients
Irinotecan Results Continue to Be Encouraging in Colorectal Cancer
Irinotecan Active in Pediatric Cancers
Combined Modality Therapy Has Enhanced Activity in Locally Advanced Rectal Cancer
Ultrasound Contrast Agents Help Diagnose Prostate Cancer
Optimal Use of Irinotecan Still to be Determined
Groups Urge Federal Action Against Eclipse Cigarettes
Potential Advantages of Oral Irinotecan Defined in Phase I Studies
New Website for Cancer Pain Patients
Creative Center for Women With Cancer Adds the Performing Arts
More Precise Surrogate Markers for Clinical Response Are Needed
Rubitecan Appears Active in Advanced Pancreatic Cancer
Physicians Must Unite Against New Bureaucratic ‘Hassles’ to Practicing Medicine

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Related Content

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.

HAIC Regimen Yields Long-Term Survival in Unresectable HCC

Russ Conroy
July 8th 2025
Article

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


Exercise-Based Regimen Shows Efficacy Promise in CRC

Exercise-Based Regimen Shows Efficacy Promise in CRC

Ariana Pelosci
June 30th 2025
Article

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

Related Content

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.

HAIC Regimen Yields Long-Term Survival in Unresectable HCC

Russ Conroy
July 8th 2025
Article

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.

Zanidatamab Combo Has Meaningful Activity in HER2+ Gastroesophageal Cancer

Russ Conroy
July 5th 2025
Article

Confirmatory data may support zanidatamab as an advancement in the treatment of HER2-positive advanced gastroesophageal adenocarcinoma.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.

Zanidatamab Receives EU Conditional Marketing Authorization in HER2+ BTC

Roman Fabbricatore
July 2nd 2025
Article

Data from the HERIZON-BTC-01 trial evaluating zanidatamab in previously treated, unresectable HER2-positive biliary tract cancer support the decision.


Exercise-Based Regimen Shows Efficacy Promise in CRC

Exercise-Based Regimen Shows Efficacy Promise in CRC

Ariana Pelosci
June 30th 2025
Article

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.